SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

Acadia Reports Third-Quarter 2026 Financial Results

Acadia reported third-quarter revenue of $342 million, citing continued commercial momentum across DAYBUE and NUPLAZID.

ACAD

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD), today announced its financial results for the third quarter ended September 30, 2026.“Acadia delivered a strong third quarter, with total revenues of $342 million and continued commercial momentum across DAYBUE and NUPLAZID,” said Catherine Owen Adams, Chi…

Related stories